Physician profile
Jill Sharp
NPI 1295880938
$1,529.21
in general payments reported to CMS, 2019-2025
15 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.35 · 2023: $524 · 2024: $295 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.07 |
| Education | $145.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.79 | 2023-2025 | |
| Janssen Biotech, INC. | $279.76 | 2025 | Tremfya |
| Evoke Pharma, INC. | $125.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $101.20 | 2023 | Zeposia |
| Pfizer INC. | $98.60 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $98.37 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $84.48 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.73 | 2023-2024 | Xifaxan, Trulance |
| Celltrion USA INC. | $35.25 | 2024-2025 | Vegzelma |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Genzyme Corporation | $21.72 | 2024 | |
| Organon LLC | $18.74 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.66 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.30 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.